!-- Start Popup -->

Alps Advisors Increased Emergent Biosolutions (EBS) Position; Bio Rad Laboratories (BIO)’s Sentiment Is 1.03

August 7, 2018 - By Eric Painter

Emergent BioSolutions Inc. (NYSE:EBS) Logo

Alps Advisors Inc increased Emergent Biosolutions Inc (EBS) stake by 29.72% reported in 2018Q1 SEC filing. Alps Advisors Inc acquired 17,266 shares as Emergent Biosolutions Inc (EBS)’s stock rose 0.71%. The Alps Advisors Inc holds 75,360 shares with $3.97M value, up from 58,094 last quarter. Emergent Biosolutions Inc now has $2.73 billion valuation. The stock decreased 3.46% or $1.96 during the last trading session, reaching $54.65. About 303,785 shares traded. Emergent BioSolutions Inc. (NYSE:EBS) has risen 65.53% since August 7, 2017 and is uptrending. It has outperformed by 52.96% the S&P500. Some Historical EBS News: 03/05/2018 – EMERGENT BIOSOLUTIONS INC EBS.N FY2018 SHR VIEW $2.38, REV VIEW $731.4 MLN — THOMSON REUTERS l/B/E/S; 22/03/2018 – EMERGENT BIOSOLUTIONS INC – REPURCHASE PROGRAM WILL BE FUNDED USING COMPANY’S WORKING CAPITAL; 05/03/2018 GILEAD SCIENCES INC – NO PATIENTS IN BIKTARVY TREATMENT ARM DEMONSTRATED TREATMENT-EMERGENT RESISTANCE THROUGH 48 WEEKS; 03/05/2018 – EMERGENT BIO 1Q REV. $117.8M, EST. $140.0M; 31/05/2018 – SPROTT INVESTS IN EMERGENT BEFORE GOLD BLOCKCHAIN PLATFORM; 24/05/2018 – CEPI – PROFECTUS WILL RECEIVE DEVELOPMENT FUNDING FOR ADVANCING ITS NIPAH VIRUS VACCINE AND EMERGENT WILL PROVIDE TECHNICAL AND MANUFACTURING SUPPORT; 22/03/2018 – EMERGENT BIOSOLUTIONS – TERM OF BOARD AUTHORIZATION OF REPURCHASE PROGRAM IS UNTIL DEC 31, 2019; 27/03/2018 – Emergent Technology Holdings is hoping to digitally encode the gold supply chain using blockchain tech in the first half of this year; 26/03/2018 – Emergent Board of Directors Promotes Robert Kramer Sr. to Newly Created Position of President and Chief Operating Officer; 24/05/2018 – CEPI – COLLABORATION WITH PROFECTUS BIOSCIENCES INC. AND EMERGENT BIOSOLUTIONS INC

Bio Rad Laboratories Inc (BIO) investors sentiment decreased to 1.03 in Q1 2018. It’s down -0.10, from 1.13 in 2017Q4. The ratio turned negative, as 123 active investment managers increased and started new stock positions, while 119 reduced and sold equity positions in Bio Rad Laboratories Inc. The active investment managers in our database now own: 18.53 million shares, down from 18.57 million shares in 2017Q4. Also, the number of active investment managers holding Bio Rad Laboratories Inc in top ten stock positions decreased from 4 to 3 for a decrease of 1. Sold All: 18 Reduced: 101 Increased: 81 New Position: 42.

Tikvah Management Llc holds 11.48% of its portfolio in Bio-Rad Laboratories, Inc. for 149,407 shares. Sector Gamma As owns 94,240 shares or 4.25% of their US portfolio. Moreover, Beaconlight Capital Llc has 3.52% invested in the company for 37,490 shares. The Georgia-based Atlanta Capital Management Co L L C has invested 1.9% in the stock. Hitchwood Capital Management Lp, a New York-based fund reported 150,000 shares.

Bio-Rad Laboratories, Inc. manufactures and supplies products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components for life science research, healthcare, analytical chemistry, and other markets. The company has market cap of $9.40 billion. The firm operates through two divisions, Life Science and Clinical Diagnostics. It has a 12.38 P/E ratio. The Life Science segment develops, makes, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

Since January 1, 0001, it had 0 insider purchases, and 1 sale for $106,197 activity.

The stock increased 1.05% or $3.27 during the last trading session, reaching $315.45. About 156,376 shares traded or 9.55% up from the average. Bio-Rad Laboratories, Inc. (BIO) has risen 30.04% since August 7, 2017 and is uptrending. It has outperformed by 17.47% the S&P500. Some Historical BIO News: 08/05/2018 – BIO-RAD SEES FY REV. CHANGE EX-FX +3.5% TO +4%; 08/05/2018 – Bio-Rad Laboratories 1Q EPS $21.77; 16/03/2018 – Bio-Rad Laboratories Says Intends to Complete Filing as Promptly as Possible; 08/05/2018 – BIO-RAD 1Q EPS $21.77, EST. $1.040; 09/05/2018 – NYSE HALT BIO-RAD LABS B BlOb.N ADDITIONAL INFORMATION LAST $250.85000; 16/03/2018 – BIO RAD LABORATORIES SAYS UNABLE TO FILE 2017 FORM 10-K BY EXTENDED FILING DEADLINE OF MARCH 16; 30/04/2018 – Bio-Rad Closes Below 50-Day Moving Average: Technicals; 16/03/2018 – Bio-Rad Laboratories Cites Continuing Review, Audit by KPMG; 16/03/2018 – BIO RAD LABORATORIES SAYS IDENTIFIED CERTAIN INTERNAL CONTROL DEFICIENCIES ARISING FROM APRIL 2017 ERP SYSTEM & BUSINESS STRUCTURE CONVERSION; 14/05/2018 – Clinton Group Adds Dominion Energy, Exits PPL, Cuts Bio-Rad: 13F

More important recent Bio-Rad Laboratories, Inc. (NYSE:BIO) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: Denali’s Parkinson’s Candidate Clears Early-Stage Trials, Dexcom’s Strong Quarter” on August 02, 2018, also Businesswire.com published article titled: “Bio-Rad to Report Second-Quarter 2018 Financial Results Tuesday, August 7, 2018”, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: Merck’s Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile” on July 26, 2018. More interesting news about Bio-Rad Laboratories, Inc. (NYSE:BIO) was released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold” with publication date: July 26, 2018.

Among 4 analysts covering Emergent BioSolutions (NYSE:EBS), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Emergent BioSolutions had 4 analyst reports since February 27, 2018 according to SRatingsIntel. Singular Research maintained the shares of EBS in report on Tuesday, February 27 with “Buy” rating. The rating was initiated by Cantor Fitzgerald with “Buy” on Monday, June 11. The rating was downgraded by Wells Fargo to “Hold” on Tuesday, April 24.

Since February 27, 2018, it had 0 insider purchases, and 10 selling transactions for $3.64 million activity. Havey Adam sold $93,951 worth of stock or 1,898 shares. The insider El-Hibri Fuad sold $804,150. Richard Ronald sold 7,893 shares worth $434,115. Zoon Kathryn C sold 1,377 shares worth $70,434. JOULWAN GEORGE A had sold 5,000 shares worth $264,448. $822,615 worth of Emergent BioSolutions Inc. (NYSE:EBS) was sold by Abdun-Nabi Daniel on Tuesday, June 5. Shares for $436,876 were sold by Hauer Jerome M on Tuesday, June 5.

More recent Emergent BioSolutions Inc. (NYSE:EBS) news were published by: Streetinsider.com which released: “Emergent BioSolutions (EBS) Commences Phase 1 Clinical Study of Zika Virus Immune Globulin Therapeutic” on July 31, 2018. Also Benzinga.com published the news titled: “The Daily Biotech Pulse: Denali’s Parkinson’s Candidate Clears Early-Stage Trials, Dexcom’s Strong Quarter” on August 02, 2018. Benzinga.com‘s news article titled: “The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs” with publication date: July 28, 2018 was also an interesting one.

Investors sentiment decreased to 1.77 in 2018 Q1. Its down 0.25, from 2.02 in 2017Q4. It dropped, as 10 investors sold EBS shares while 65 reduced holdings. 56 funds opened positions while 77 raised stakes. 38.34 million shares or 3.95% more from 36.89 million shares in 2017Q4 were reported. Pub Sector Pension Board holds 0.02% or 49,077 shares in its portfolio. Fil has invested 0.02% in Emergent BioSolutions Inc. (NYSE:EBS). Envestnet Asset Incorporated owns 7,302 shares for 0% of their portfolio. Mason Street Advisors Limited Liability reported 9,731 shares stake. Bnp Paribas Arbitrage Sa has 0% invested in Emergent BioSolutions Inc. (NYSE:EBS). Parametric Ltd Limited Liability Company has 0.01% invested in Emergent BioSolutions Inc. (NYSE:EBS) for 237,330 shares. 407 are owned by Dubuque Bankshares And. Blackrock invested in 0.01% or 4.47M shares. Comerica Bancorp holds 0.03% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS) for 65,614 shares. Citadel Advsrs Lc has 16,064 shares. Da Davidson & reported 4,048 shares. Washington Trust Fincl Bank holds 0% in Emergent BioSolutions Inc. (NYSE:EBS) or 176 shares. Moreover, Bogle Management Limited Partnership De has 0.54% invested in Emergent BioSolutions Inc. (NYSE:EBS) for 136,638 shares. Yorktown Mngmt And Com Inc has invested 0.13% in Emergent BioSolutions Inc. (NYSE:EBS). Parametrica holds 0.29% or 4,434 shares.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts